US Health Official Robert F. Kennedy Jr. Accuses Medical Journals of Corruption

In a controversial statement, US Health Secretary Robert F. Kennedy Jr. has openly accused prominent medical journals of corruption, alleging that they are heavily influenced and controlled by the pharmaceutical industry. Kennedy, known for promoting vaccine misinformation and advocating for sweeping reforms in federal public health policies, made his remarks during a podcast where he targeted prestigious publications such as The Lancet, The New England Journal of Medicine, and JAMA.

Kennedy announced that his department is considering halting publication submissions to these journals, citing concerns over njih credibility and independence. He proclaimed, "We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and other major journals because they're all corrupt," and suggested that without significant changes, the National Institutes of Health (NIH) scientists might be prohibited from publishing there.

Kennedy has historically criticized the influence of the pharmaceutical industry within the US healthcare system. He claims that these journals, which have historically played a crucial role in advancing biomedical research through peer-reviewed studies, are compromised. He argues that the high costs associated with publishing—such as the $10,000 fee often required to publish a study—allow pharmaceutical companies to manipulate the research outcomes that get published.

The allegations are supported by references to past critiques, notably from Marcia Angell, a former senior editor at the New England Journal of Medicine. In the early 2000s, Angell authored a book asserting that much of the current clinical research is unreliable due to industry interference.

Kennedy’s accusations extend to various health agencies under his authority, which he claims are too closely tied to pharmaceutical interests. This stance forms part of his broader effort to overhaul departments, reduce bureaucratic corruption, and restore public trust in healthcare authorities.

While these claims are highly contentious and have received widespread criticism from the scientific community, Kennedy's remarks have ignited debate about the integrity of medical publishing and the influence of big pharma on scientific research. For further details, refer to the original report at source.